Abstract
The principle of selective targeting of immunotoxins lies on the basis that cancer cells usually have few or specific growth factors/receptors/antigens highly over expressed on their surface. Ligands corresponding to these molecules are conjugated to modified toxins (modified to loss its native function) isolated form variety of bacterial populations. Normal cells either do not express these molecules or express at relatively low number leading to no or minimal adverse effects. The basic mechanism of action of these immunotoxins depends on the toxins employed. In this regard continuous efforts are being made to (i) Identity molecules exclusively expressed in cancer cells, (ii) to improve the specificity and efficacy (iii) reduce size effects of the drugs, (iv) Reduce immunogenicity and (v) to improve better pharmacokinetics for drugs delivery.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
N. Arora, R. Masood, T. Zhenq, J. Cai, D.L. Smith, P.S. Gill, Cancer Res. 59, 183–188 (1999)
F. Benchetrit, A. Gazagne, O. Adotevi, N. Haicheur, B. Godard, C. Badoual, W.H. Fridman, E. Tartour, Bull. Cancer 90, 677–685 (2003)
W.F. Benedict, M.S. Baker, L. Haroun, E. Choi, B.N. Ames, Cancer Res. 37, 2203–2213 (1977)
M.J. Bennett, D. Eisenberg, Protein Sci. 3, 1464–1475 (1994)
R.E. Bird, Science 242, 423–426 (1988)
J. Brierley, Can. Med. Assoc. J. 174, 155–156 (2006)
U. Brinkman, E. Brinkmann, M. Gallo et al., Proc. Natl. Acad. Sci. USA 92, 10427–10431 (1995)
T.M. Chang, A. Dazord, D.M. Neville Jr., J. Biol. Chem. 252, 1515–1522 (1977)
S. Choe, M.J. Bennett, G. Fujii, P.M. Curmi, K.A. Kantardjieff, R.J. Collier, D. Eisenberg, Nature 357, 216–222 (1992)
B.A. Conley, M.J. Egorin, N. Tait, D.M. Rosen, E.A. Sausville, G. Dover, R.J. Fram, D.A. Van Echo, Cancer Res. 4, 629–634 (1998)
A. De Zoysa, A. Efstratiou, P.M. Hawkey, J. Clin. Microbiol. 43, 223–228 (2005)
M. Duvic, J. Cather, J. Maize, A.E. Frankel, Am. J. Hematol. 58, 87–90 (1998)
S. Elisabeth, J. Elke, C. Yao-Tseng, J.S. Matthew, G. Ivan, K. Julia, A. Michael, K. Alexander, J.O. Lloyd, J. Exp. Med. 187(8), 1349–1354 (1998)
D. FitzGerald, I. Pastan, J. Natl. Cancer Inst. 81, 1455–1463 (1989)
G. Fourel, A. Phalipon, M. Kaczorek, Infect. Immun. 57, 3221–3225 (1989)
A.E. Frankel, Leuk. Res. 26, 1069–1071 (2002)
A.E. Frankel, P.D. Hall, C. Burbage, J. Vesly, M. Willingham, K. Bhalla, R.J. Kreitman, Blood 90, 3654–3661 (1997)
A.E. Frankel, J. Ramage, M. Kiser, R. Alexander, G. Kucera, M.S. Miller, Protein Eng. 13, 575–581 (2000)
A.E. Frankel, D.R. Fleming, B.L. Powell, R. Gartenhaus, Expert Opin. Boil. Ther. 3, 179–186 (2003)
G. Gorgun, F. Foss, Blood 100, 1399–1403 (2002)
M.K. Gospodarowicz, D. Miller, P.A. Groome, F.L. Greene, P.A. Logan, L.H. Sobin, Cancer 100, 1–5 (2004)
A.B. Gottlieb, J.D. Bos, Clin. Immunol. 105, 105–116 (2002)
L. Greenfield, V.G. Johnson, R.J. Youle, Science 238, 536–539 (1987)
R.B. Herberman, Semin. Oncol. 29, 27–30 (2002)
H.Y. Hu, P.D. Huynh, J.R. Murphy, J.C. Vanderspek, Protein Eng. 11, 811–817 (1998)
K. Hung, R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, H. Levitsky, J. Exp. Med. 188, 2357–2368 (1998)
J.S. Huston, D. Levinson, M. Mudgett-Huntor, M.S. Tai, J. Novotny, M.N. Margolies, Proc. Natl. Acad. Sci. 85, 5879–5883 (1988)
M. Introna, A. Mantovani, Cancer Metastasis Rev. 2, 337–350 (1983)
B.L. Kagan, A. Finkelstein, M. Colombini, Proc. Natl. Acad. Sci. 78, 4950–4954 (1981)
A. Keppler-Hafkemeyer, R.J. Kreitman, I. Pastan, Int. J. Cancer 87, 86–94 (2000)
K. Kim, A.D. Vallera, H. Ni, H.K. Cho, R.S. Spellman, C.W. Low, A.W. Hall, Int. Congr. Ser. 1247, 185–197 (2002)
R. Kreitman, J. BioDrugs 23(1), 1–13 (2009)
R.J. Kreitman, I. Pastan, Biochem. J. 307, 29–37 (1995)
R.J. Kreitman, J.K. Batra, S. Seetharam et al., Bioconjug. Chem. 4, 112–120 (1993)
C.F. LeMaistre, M.N. Saleh, T.M. Kuzel, F. Foss, L.C. Platanias, G. Schwartz, M. Ratain, A. Rook, C.O. Freytes, F. Craiq, J. Reuben, J.C. Nichols, Blood 91, 399–405 (1998)
B.Y. Li, S. Ramakrishnan, J. Biol. Chem. 269, 2652–2658 (1994)
D. Liger, J.C. Vanderspek, C. Gaillard, C. Cansier, J.R. Murphy, P. Leboulch, D. Gillet, FEBS Lett. 406, 157–161 (1997)
S. Liu, G.T. Milne, J.G. Kuremsky, G.R. Fink, S.H. Leppla, Mol. Cell. Biol. 24, 9487–9497 (2004a)
T.F. Liu, J.O. Urieto, J.E. Moore, M.S. Miller, A.C. Lowe, A. Thorburn, A.E. Frankel, Exp. Haematol. 32, 277–281 (2004b)
B. Lores, J.M. Garcia-Estevez, C. Arias, Int. J. Mol. Med. 4, 729–733 (1998)
S. Marchini, M. D’Incalci, M. Broggini, Curr. Med. Chem. Anti-Cancer Agents 4, 247–262 (2004)
M. Mrudula, R.S. Verma, Cancer Sci. 100(8), 1359–1365 (2009): Impact
S. Nakamura, M. Terashima, N. Kikuchi, M. Kimura, T. Maehara, A. Saito, M. Sato, BMC Nephrol. 5, 4 (2004)
D.M. Neville Jr., K. Srinivasachar, R. Stone, J. Scharff, J. Biol. Chem. 264, 14653–14661 (1989)
L.J. Old, Cancer Res. 41, 361–375 (1981)
L.D. Phan, J.P. Perentesis, J.W. Bodley, J. Biol. Chem. 268(12), 8665–8668 (1993)
S. Potala, S. Sahoo, R.S. Verma, Drug Discov. Today Rev. 13(17/18), 807–815 (2008)
C. Queen, W.P. Schneider, H.E. Selick, P.W. Payne, N.F. Landolfi, J.F. Duncan, N.M. Avdalvic, M. Levitt, R.P. Junghans, T.A. Waldmann, Proc. Natl. Acad. Sci. 86, 10029–10033 (1989)
Y. Reiter, Cancer Res. 54, 2714–2718 (1994)
J. Ren, K. Kachel, H. Kim, S.E. Malenbaum, R.J. Collier, E. London, Science 284, 955–957 (1999a)
J. Ren, J.C. Sharpe, R.J. Collier, E. London, Biochemistry 38, 976–984 (1999b)
D.A. Rew, G.D. Wilson, Eur. J. Surg. Oncol. 26, 227–238 (2000)
S. Seetharam, V.K. Chaudhary, D. FitzGerald, I. Pastan, Biol. Chem. 266, 17376–17381 (1991)
R.H. Shao, X. Tian, G. Gorgun, A.G. Urbano, F.M. Foss, Leuk. Res. 26, 1077–1083 (2002)
N. Sidell, U. Kummer, D. Aframian, S. Thierfelder, Cell. Immunol. 179, 116–125 (1997)
C.B. Siegall, V.K. Chaudhary, D.J. FitzGerald et al., J. Biol. Chem. 264, 14256–14261 (1989)
J. Thorburn, A.E. Frankel, A. Thorburn, Clin. Cancer Res. 9, 861–865 (2003)
R.E. Toes, F. Ossendorp, R. Offringa, C.J. Melief, J. Exp. Med. 189, 753–756 (1999)
J.O. Urieto, T. Liu, J.H. Black, K.A. Cohen, P.D. Hall, M.C. Willingham, L.K. Pennell, D.E. Hogge, R.J. Kreitman, A.E. Frankel, Protein Expr. Purif. 33, 123–133 (2004)
B.G. Van Ness, J.B. Howard, J.W. Bodley, J. Biol. Chem. 255, 10717–10720 (1980)
J.C. Vanderspek, J.A. Sutherland, M. Ratnarathorn, K. Howland, T.L. Ciardelli, J.R. Murphy, J. Biol. Chem. 271, 12145–12149 (1996)
T.G. Woodworth, Clin. Exp. Rheumatol. 11, S177–S180 (1993)
W. Zumkeller, P.N. Schofield, Anticancer Res. 15, 343–348 (1995)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Verma, R.S., Potala, S., Mathew, M., Choudhary, S. (2012). Application of Microbial Toxins for Cancer Therapy. In: Satyanarayana, T., Johri, B. (eds) Microorganisms in Sustainable Agriculture and Biotechnology. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-2214-9_28
Download citation
DOI: https://doi.org/10.1007/978-94-007-2214-9_28
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-2213-2
Online ISBN: 978-94-007-2214-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)